In contrast to the pro-angiogenic effect in the ischemic myocardium, TXL treatment substantially attenuated VV neovascularization in murine advanced atherosclerotic lesions by inhibiting inflammatory angiogenesis via BMX/NF-κB/MAPK pathways, leading to enhanced plaque stabilization [15]. This evidence concerns the gene NFKB1 and Atherosclerotic lesion.